Searchable abstracts of presentations at key conferences in endocrinology

ea0063p216 | Diabetes, Obesity and Metabolism 1 | ECE2019

Please Don’t Sugarcoat it: An avoidable case of Euglycaemic DKA in the setting of a SGLT-2 Inhibitor

Tansey David J , Pazderska Agnieska

Intro: Diabetic Ketoacidosis (DKA) is a medical emergency characterised by hyperglycemia, ketosis and acidosis. If left untreated it can lead to cerebral oedema, acute kidney injury, Adult Respiratory Distress Syndrome andeven death. Euglycaemic DKA (EuDKA) without hyperglycaemia is rare but increasing cases of EuDKAbeing reported in patients taking SGLT2 inhibitors.Case report: A 53 year old, Type 2 Diabetic was admitted for an elective cholecystecomy. ...

ea0077p205 | Metabolism, Obesity and Diabetes | SFEBES2021

Assessing and Improving junior doctors’ knowledge and confidence in managing Diabetes Mellitus in the end-of-life setting

Tansey David J. , Tiernan Eoin , Moran Carla

An anonymised online survey was created to evaluate junior doctor’s competency and confidence with decision-making scenarios in managing patients with diabetes at the end-of-life. 26 doctors working at the Beacon Hospital completed the online survey. A structured education programme was then delivered to the junior doctors where the critical information pertaining to the management of diabetes at the end-of-life was discussed, based on the ABCD 2011 and Diabetes UK 2013 a...

ea0059ep97 | Thyroid | SFEBES2018

The Use of Salvage Radiotherapy and Radioactive Iodine in a Case of Recurrent Metastatic Papillary Thyroid Cancer: A Case Report

Tansey David J , Gibney James , Salib Osama

Background: Thyroid carcinoma consists of just 1% of all malignancies but is the commonest malignant endocrine tumour. Papillary thyroid carcinoma is the most common form of thyroid carcinoma consisting of 80% of all cases. There are very few case reports in the literature of papillary thyroid cancers presenting with distant to the pelvic organs. Distant metastases are noted in 1–3% of patients with thyroid cancer at initial diagnosis.Clinical case:...

ea0061p001 | (1) | OU2019

GLP-1 agonist use in the management of obesity in Type 2 Diabetes: an Irish tertiary hospital experience

Tansey David J , Healy Marie Louise , Pazderska Agnieszka

Background: In Clinical Trials, Glucagon-like peptide-1 (GLP-1) receptor analogs liraglutide and semaglutide have been shown to cause weight loss, reduced systolic blood pressure, effectiveglycemic control with low rates of hypoglycemia, in patients with type 2 diabetes. Through a retrospective clinical study, the authors aimed to assess the clinical effectiveness of GLP-1 receptor agonists in the management of obesity in patients with Type 2 Diabetes.Me...